Fractional Carbon Dioxide Laser,Topical Corticosteroid and Narrow Band Ultraviolet B in Treatment of Stable Vitiligo

• Status: Unknown status
• Trial end date: 2019-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Vitiligo is an acquired disease with a variable course. It is characterized clinically by well-defined depigmented macules or patches thought to occur secondary to melanocyte dysfunction and loss. it is the most common depigmentation disorder, affecting approximately 0.5 to 2.0 percent of the population and has no predilection for gender or race .

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University

Criteria

Inclusion Criteria:

• Patient age ≥ 14 years old.

• Any sex

Exclusion Criteria:

• Patients less than 14 years old.

• Patients with new, spreading lesions of vitiligo within the preceding 6 months.

• Pregnant female patients.

• Patients with history of keloid formation.